Navigation Links
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Date:2/26/2008

-free survival, confirmed response rate, duration of response, disease control rate and safety.

The Phase 3 NSCLC monotherapy trial will be conducted concurrently with the pivotal Phase 3 first-line combination with chemotherapy NSCLC trial. Both studies will be conducted at many of the same sites and in partnership with the same global contract research organization (CRO). The first-line Phase 3 trial is also supported by a positive double-blind, placebo-controlled Phase 2 trial. For the first-line indication, Agennix has been granted a Special Protocol Assessment and Fast Track designation from the FDA, and has received favorable Scientific Advice from the EMEA. Both Phase 3 studies are expected to be active and recruiting in mid-2008.

FDA Fast Track Designation and EMEA Favorable Scientific Advice

Agennix received Fast Track designation from the FDA for the clinical development of talactoferrin as a single-agent in patients with locally advanced or metastatic NSCLC who have failed at least two prior systemic anti- cancer therapies. The Company had previously received Fast Track designation for first-line treatment of NSCLC in combination with chemotherapy.

Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and address unmet medical needs. The NSCLC monotherapy Fast Track designation was granted based on positive, randomized, placebo-controlled Phase 2 results with oral talactoferrin, and the planned Phase 3 pivotal trial.

"We are very pleased that the FDA recognizes that our lead product, talactoferrin alfa, also has potential as a single-agent treatment for patients with NSCLC who have failed previous therapies and who currently have very few options," said Dr. Rajesh Malik, Chief Medical Officer of Agennix.

Agennix also received Scientific Advice from the EMEA indicating that the planned single pivotal Phase 3 global trial with talactof
'/>"/>

SOURCE Agennix
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
7. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
8. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
(Date:7/24/2014)...  Perrigo Company (NYSE: PRGO ; TASE) ... equivalent rating from the U.S. Food and Drug Administration ... for testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone ... can be substituted with the full expectation that it ... as AndroGel 1% when used under the conditions specified ...
(Date:7/24/2014)... July 24, 2014 Talyst, a market leader ... National Association of State Veterans Homes (NASVH) Summer Conference ... goal of the NASVH is to ensure that each ... long term health care and respect which they have ... With the InSite® Remote Dispensing System, Talyst can help ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... a rattler may be a minor challenge for Rooster Cogburn ... , but proper handling of poor Mattie,s snakebite was a ... unknowingly perpetuates Hollywood myth by doing precisely the opposite of ... when it comes to the need for speed in seeking ...
... -- China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: ... products in China, today announced that it plans to release ... on Thursday, March 3, 2011. The Company ... March 3, 2011 to discuss fiscal year 2010 results. Listeners ...
Cached Medicine Technology:Oscar-Nominated True Grit Gets Top Reviews for Acting but Mixed Reviews for Snakebite Treatment 2Oscar-Nominated True Grit Gets Top Reviews for Acting but Mixed Reviews for Snakebite Treatment 3China Pharma Holdings, Inc. to Report Fiscal Year 2010 Financial Results on March 3, 2011 2
(Date:7/25/2014)... July 25, 2014 iTanSmart is a ... iPads. The app provides a tailored approach to eliminating ... dangerous sunburns and skin damage. In his review, Eaton ... and capabilities of iTanSmart. , Eaton begins his ... as a ‘better organized’ and ‘great alternative’ to its ...
(Date:7/25/2014)... to the Addict Him To You Pdf review recently updated ... women how to get the love of the man they ... this book consists of 4 parts, including:, ... (and what to do about it) ,     Part 2: ...     Part 3: How to touch his heart deeply and capture ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 As the category ... of Xoçai is to transform and improve individual ... , Adam Paul Green a successful Austin, Texas ... Japan at the end of the July to promote the ... in September 2014. , Eric Worre has been a leader ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 At World ... DC July 19, 17 participating developmentally-disabled teens and young ... even if off-road bicycling, canoeing and hiking can be ... non-profit at the scenic Chesapeake and Ohio Canal ... participating athletes both disabled and able-bodied. Under slightly overcast ...
(Date:7/24/2014)... 2014 iFitDress.com, a renowned wedding dress ... of casual party dresses . According to the ... are now offered at discounted prices, up to 59% ... until August 04. , Most of the casual ... global market. They are popular for special designs, delicate ...
Breaking Medicine News(10 mins):Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... end-stage renal disease who opt for peritoneal dialysis experience no ... a retrospective study at UT Southwestern Medical Center has found. ... body and provides greater mobility than hemodialysis, the more common ... peritoneal dialysis, have a better quality of life and the ...
... HealthDay Reporter , WEDNESDAY, March 2 (HealthDay News) -- ... it plans to remove about 500 unapproved prescription cough, ... drugs have not been evaluated by the FDA for ... take than approved over-the-counter (OTC) drugs that treat these ...
... of death and disease in the U.S., with more than ... And yet teens still smoke. Indeed, smoking usually begins in ... became hooked by the time they were 18. Meanwhile, teens ... While studies have linked cigarette smoking to deficits in ...
... protein p53 is the most frequently mutated in human cancer. ... that it acts primarily as a regulator of how genes ... Pennsylvania School of Medicine show that the protein has at ... sugar glucose, one of body,s main sources of fuel. These ...
... tests and imaging can sometimes help diagnose juvenile idiopathic ... are the most valuable tools in identifying this disease. ... Journal of the American Academy of Orthopaedic Surgeons ... and imaging studies meant to screen for juvenile arthritis ...
... quantitativenot qualitativedata analysis has demonstrated that time-of-flight (TOF) ... detection. Research published in the March issue of ... that oncologic TOF fluorodeoxyglucose (FDG) PET scans yielded ... liver cancers over all contrasts and body mass ...
Cached Medicine News:Health News:Portable, less costly peritoneal dialysis shows no additional catheter risk factors 2Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 2Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 3Health News:Tobacco smoking impacts teens' brains, UCLA study shows 2Health News:Tobacco smoking impacts teens' brains, UCLA study shows 3Health News:Penn researchers find new role for cancer protein p53 2Health News:Penn researchers find new role for cancer protein p53 3Health News:Joint pain in children: Is it just a sore knee, or ... ? 2Health News:Improved lesion detection with time-of-flight PET scans affirmed 2
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... Accu-Temp Cauteries provide a broad ... in a wide variety of ophthalmic ... packaged sterile, complete with a safety ... "off " position when not in ...
... The Luminary LASIK Light Probes provide ... that allows the corneal interface to be ... use of the Tindal effect and light ... of interface debris, epithelial deposits, flap edge ...
... EEG system designed to satisfy the needs ... center. Ready to use, Comet XL is ... and Photic Stimulator. Select from various mobile ... your individual needs. These powerful, easy-to-use EEG ...
Medicine Products: